SIL-1RA AND ICIL-1RA PRODUCTION BY MONOCYTE DERIVED CELL

单核细胞衍生细胞产生 SIL-1RA 和 ICIL-1RA

• 批准号: 2077393
• 负责人: MARK MALYAK
• 金额: $ 7.56万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-15 至 1997-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2077393
• 关键词: RNA splicing; SDS polyacrylamide gel electrophoresis; cell differentiation; cell type; complementary DNA; cytokine receptors; enzyme linked immunosorbent assay; epithelium; genetic transcription; glycosylation; growth factor receptors; growth media; human tissue; inflammation; inhibitor /antagonist; interleukin 1; intracellular; keratinocyte; macrophage; messenger RNA; monocyte; polymerase chain reaction; protein biosynthesis; protein signal sequence; secretory protein; tissue /cell culture

Interleukin-1 receptor antagonist (IL-1ra) exists in two forms which are produced through alternate start sites and internal splicing of a single gene. Secretory IL-1ra (sIL-1ra) has a leader sequence, is secreted, is a significant product of monocytes, and probably functions as an antagonist of extracellular IL-1. Intracellular IL-1ra (icIL-1ra) lacks a leader sequence, probably remains predominantly intracellular, is a significant product of epithelial cells, and may function as an antagonist of intracellular IL-1. The hypothesis to be examined in these studies is that monocyte/macrophage cells produce both sIL-1ra and icIL-1ra. It is further hypothesized production of both forms of IL-1ra by these cells is regulated separately. Four specific aims will be pursued: 1) to accurately quantitate sIL-1ra and icIL-1ra mRNA utilizing quantitative PCR techniques, 2)to accurately quantitate sIL-1ra and icIL-1ra protein concentrations utilizing a sensitive and specific ELISA, 3) to examine the differential regulation of sIL-1ra and icIL-1ra mRNA and protein production in different cell types, and 4) to examine the potential biologic role of icIL-1ra. The results of these studies should clarify the possible in vivo relevance of sIL-1ra and icIL-1ra in rheumatoid arthritis and in other chronic inflammatory diseases.

白细胞介素-1受体拮抗剂（IL-1ra）以两种形式存在